Please enable JS

AB-Cube

Founded in 2006, AB-Cube revolutionised the life sciences and international healthcare industry with a cloud-based vigilance solution for management of adverse events. They offer a wide range of dedicated solutions like pharmacovigilance, medical device safety, nutrivigilance and CosmEthics® for cosmetovigilance.

 

They have a diverse international client base, consisting of organisations, academia, CROs and pharmaceutical companies, who are proud to collaborate with AB-Cube  for their pharmacovigilance needs.

 

Learn more: www.ab-cube.com

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

What role does AI play in lung cancer screening?

December 13, 2025

Mind Health With 53,000 new cases diagnosed each year, lung cancer is the deadliest cancer in France, according to data from the National Cancer Institute. Three-quarters of cases are detected at an advanced stage, which reduces the chances of recovery. The importance of screening is therefore crucial. In this field, the combination of low-dose CT […]

READ MORE
telemedecine technologies news

Quality Isn’t Just a Checkbox — Can Better Workforce Skills Drive Lower Costs?

November 27, 2025

Med City News Healthcare quality isn’t improving at scale, despite advances in technology, because many systems treat it as another compliance task rather than a priority. Stephanie Mercado, CEO of the National Association for Healthcare Quality (NAHQ), argued that investing in workforce skills and standardizing roles can drive safer, higher-quality care while delivering measurable cost […]

READ MORE
telemedecine technologies news

Truth in Reporting Clinical Trial Efficacy: A Call for Action

November 27, 2025

Trial Site News Clinical trial reporting of treatment efficacy is the foundation of public trust in medicine. Yet pharmaceutical companies often report efficacy measured as a relative risk reduction (RRR) while omitting the more relevant absolute risk reduction (ARR). This statistical sleight of hand can make clinically insignificant benefits look spectacular! Consider a simple example A risk is […]

READ MORE